Wall Street Brunch: CPI With A Twist Due

July CPI is expected to show a modest rise, though economists anticipate consumer fatigue will temper inflation's acceleration in H2, with core inflation returning to around 3% by Q4. This comes as concerns are raised over the integrity of BLS data following the commissioner's firing, ahead of July retail sales figures which are also eyed for signs of weakening consumer spending. On the corporate front, Nvidia has secured licenses to export H20 GPUs to China, while Q2 earnings season continues to show strong positive surprises, with key reports from AMC and Cisco anticipated.

Analysis

The market is bracing for key economic data, with the July CPI expected to show a monthly headline increase of 0.3% and an annual rate of 2.8%, while core inflation is forecast to rise to 3.0% annually. Commentary from Wells Fargo suggests that growing consumer fatigue may temper further price hikes, with core inflation likely to stabilize around a 3% pace in Q4. However, this data release is clouded by political concerns over the integrity of the Bureau of Labor Statistics following the dismissal of its commissioner, creating an unusual risk factor. This precedes July's retail sales figures, which are forecast to rise 0.5% but are being watched closely for signs of weakening consumer spending. On the corporate front, Q2 earnings season has been overwhelmingly positive, with 81% of S&P 500 companies beating both EPS and revenue estimates. A significant single-stock catalyst is Nvidia reportedly receiving licenses to export its H20 AI chips to China, a material positive development. Upcoming earnings include a mixed outlook for Cisco, which faces challenging order growth comps and a potential for conservative guidance after a CFO transition, and AMC Entertainment, where analysts are positive on a recovery driven by a 37% surge in U.S. box office sales despite an expected quarterly loss.

Key Decisions for Investors

• Investors should monitor the upcoming CPI and retail sales data for confirmation of the consumer fatigue thesis, while remaining aware that political controversy surrounding the BLS could introduce unusual volatility and questions about the data's credibility.
• The reported approval of Nvidia's H20 export licenses to China is a significant positive catalyst, and positions should be evaluated based on the potential for renewed revenue streams from this key market.
• For Cisco, attention should be focused on forward guidance for FY26 and commentary on order growth, as the recent CFO transition increases the risk of a conservative outlook that could overshadow a potential Q4 earnings beat.
• Speculative positions in AMC could be influenced by the strong box office recovery narrative, but this must be balanced against its underlying financial performance, including an expected net loss.
• Sarepta Therapeutics faces a significant headwind from the regulatory controversy surrounding its drug Elevidys, warranting caution and close monitoring of any further FDA-related developments.